We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck is halting its phase 3 study of Lynparza (olaparib) in advanced colorectal cancer after a midstream futility analysis found no survival benefit associated with the drug. Read More
Amarin’s fish oil-based heart drug Vascepa (icosapent ethyl) may not have been as effective as initially thought, according to a new analysis in the American Heart Association journal Circulation. Read More
More than 180 House lawmakers have sent a letter to the Biden administration pressuring the Department of Health and Human Services (HHS) to penalize companies that limit 340B drug discounts — the latest move in an ongoing tussle between drugmakers and the U.S. government. Read More
The proprietary therapy “has the potential to significantly advance the treatment of gliomas,” says Vijay Agarwal, the company’s founder and CEO, who is a practicing brain tumor surgeon. Read More
Novo Nordisk is going after Biocon Pharma, claiming patent infringement over a generic version of Novo’s weight loss drug Saxenda (liraglutide injection), a glucagon-like peptide-1 (GLP-1) receptor agonist. Read More
A postsurgical chemotherapy regimen of Roche’s Perjeta (pertuzumab) plus Herceptin (trastuzumab) and chemotherapy cut the risk of death by 28 percent compared to Herceptin and chemo alone in patients with lymph node-positive, hormone receptor-positive (HER-2) breast cancer. Read More
Eli Lilly has teamed up with China-based Triastek to use three-dimensional (3D) drug printing for targeted release in certain parts of the gastrointestinal (GI) tract. Read More
One in six men over 50 have symptoms of testosterone deficiency, but too few of them receive appropriate treatment, said Grünenthal CEO Gabriel Baertschi. Read More